Connect your AI

MaxCyte MXCT Total Current Liabilities

Total Current Liabilities at other companies

Bio-Rad LaboratoriesBIO

$917M+81.0%

Thermo Fisher ScientificTMO

$14.62B+11.0%

Ginkgo BioworksDNA

$79.6M-31.2%

Immix Biopharma, Inc.IMMX

$10.54M+13.2%

Rapid Micro BiosystemsRPID

$19.12M+27.5%

PDE

Pro-Dex, Inc.PDEX

$14.64M-20.1%

Other financials

Income statement

Revenue$9.7M-7.1%

Gross profit$8.1M-9.1%

Operating income-$6.2M+49.7%

Net income-$4.8M+53.7%

EPS (diluted)-$0.04+60.0%

Balance sheet

Cash & equivalents$14.6M-37.8%

Total debt$17.5M-7.1%

Total equity$167.9M-15.8%

Total assets$194.5M-15.4%

Cash flow

Operating cash flow-$8.2M+43.3%

CapEx$72.0K-89.0%

Free cash flow-$8.2M+45.3%

Valuation

Market cap$130.15M-46.8%

Enterprise value$133.08M-46.3%

P/S4×-2.8×

Profitability

Gross margin80.5%-0.4pp

Operating margin-141.8%+6.4pp

Net margin-121.2%+12.3pp

FCF margin-90.9%+3.7pp

Returns & leverage

Return on equity-21.3%+2.0pp

Debt / equity0.1×0.0×

Current ratio12×-0.2×

Where this comes from

Reported directly by MaxCyte in its filing.

Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.

The official record: MaxCyte’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about MaxCyte's total current liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is MaxCyte's total current liabilities?: MaxCyte (MXCT) reported total current liabilities of $10.21M in Q1 2026.
How has MaxCyte's total current liabilities changed year-over-year?: MaxCyte's total current liabilities decreased by 19.8% year-over-year, from $12.73M to $10.21M.
What is the long-term trend for MaxCyte's total current liabilities?: Over 5 years (2020 to 2025), MaxCyte's total current liabilities has grown at a 4.2% compound annual growth rate (CAGR), from $11.61M to $14.27M.
What does total current liabilities mean?: The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.